Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing st...

Descripción completa

Detalles Bibliográficos
Autores principales: Praveen, D., Puvvada, Ranadheer Chowdary, M, Vijey Aanandhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. and International Society of Chemotherapy. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128600/
https://www.ncbi.nlm.nih.gov/pubmed/32259575
http://dx.doi.org/10.1016/j.ijantimicag.2020.105967
_version_ 1783516600286052352
author Praveen, D.
Puvvada, Ranadheer Chowdary
M, Vijey Aanandhi
author_facet Praveen, D.
Puvvada, Ranadheer Chowdary
M, Vijey Aanandhi
author_sort Praveen, D.
collection PubMed
description The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.
format Online
Article
Text
id pubmed-7128600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V. and International Society of Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-71286002020-04-08 Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19 Praveen, D. Puvvada, Ranadheer Chowdary M, Vijey Aanandhi Int J Antimicrob Agents Article The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19. Elsevier B.V. and International Society of Chemotherapy. 2020-05 2020-04-04 /pmc/articles/PMC7128600/ /pubmed/32259575 http://dx.doi.org/10.1016/j.ijantimicag.2020.105967 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Praveen, D.
Puvvada, Ranadheer Chowdary
M, Vijey Aanandhi
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title_full Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title_fullStr Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title_full_unstemmed Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title_short Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
title_sort janus kinase inhibitor baricitinib is not an ideal option for management of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128600/
https://www.ncbi.nlm.nih.gov/pubmed/32259575
http://dx.doi.org/10.1016/j.ijantimicag.2020.105967
work_keys_str_mv AT praveend januskinaseinhibitorbaricitinibisnotanidealoptionformanagementofcovid19
AT puvvadaranadheerchowdary januskinaseinhibitorbaricitinibisnotanidealoptionformanagementofcovid19
AT mvijeyaanandhi januskinaseinhibitorbaricitinibisnotanidealoptionformanagementofcovid19

Ejemplares similares